{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/prescribing-information/tricyclic-antidepressants/","result":{"pageContext":{"chapter":{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants","depth":2,"htmlHeader":"<!-- begin field c56222f4-ddca-4330-8160-ab1a00fb49c3 --><h2>Tricyclic antidepressants (TCAs)</h2><!-- end field c56222f4-ddca-4330-8160-ab1a00fb49c3 -->","summary":"","htmlStringContent":"<!-- begin item 81ec6192-0870-460a-b421-ab1a00fb499e --><!-- end item 81ec6192-0870-460a-b421-ab1a00fb499e -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8b74d8be-c624-5e74-88de-7b6ca37094ca","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e4385578-b3e0-4915-a6cd-ab1a00fc3857 --><h3>Contraindications and cautions</h3><!-- end field e4385578-b3e0-4915-a6cd-ab1a00fc3857 -->","summary":"","htmlStringContent":"<!-- begin item e1d4dfc2-9586-4196-ba01-ab1a00fc381f --><!-- begin field f30368f0-87a1-4b86-b02e-ab1a00fc3857 --><ul><li><strong>Do not prescribe tricyclic antidepressants (TCAs) to people with:</strong><ul><li>Acute porphyrias.</li><li>Arrhythmias.</li><li>Heart block.</li><li>Severe hepatic impairment.</li><li>Severer renal impairment (lofepramine).</li></ul></li><li><strong>Also, do not prescribe TCAs to people:</strong><ul><li>During the manic phase of bipolar disorder.</li><li>In the immediate recovery period after myocardial infarction.</li><li>Taking a monoamine oxidase inhibitor (MAOI).</li></ul></li><li><strong>Prescribe TCAs with caution in the elderly, and to people with:</strong><ul><li>A history of bipolar disorder, or psychosis.</li><li>A significant risk of suicide.</li><li>Bradycardia.</li><li>Cardiovascular disease.</li><li>Chronic constipation.</li><li>Convulsive disorders.</li><li>Diabetes mellitus</li><li>Hyperthyroidism.</li><li>Increased intraocular pressure, or susceptible to closed-angle glaucoma.</li><li>Phaeochromocytoma.</li><li>Prostatic hypertrophy.</li><li>Uncompensated heart failure.</li><li>Urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field f30368f0-87a1-4b86-b02e-ab1a00fc3857 --><!-- end item e1d4dfc2-9586-4196-ba01-ab1a00fc381f -->","subChapters":[]},{"id":"f1b5e1ba-abdf-5529-9c77-2f495b11c99a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bc78bee2-310b-412e-a963-ab1a00fc4ba0 --><h3>Adverse effects</h3><!-- end field bc78bee2-310b-412e-a963-ab1a00fc4ba0 -->","summary":"","htmlStringContent":"<!-- begin item 7781d9d5-b0e9-4ff5-8ac6-ab1a00fc4b73 --><!-- begin field 697e6fb9-c12c-4b6a-b55d-ab1a00fc4ba0 --><ul><li><strong>Cardiac</strong> — palpitations, tachycardia (very common); AV block, bundle branch block (common).<ul><li><strong>Rarely or very rarely</strong>: arrhythmias, cardiomyopathies, torsades de pointes.</li></ul></li><li><strong>Eye</strong> — accommodation disorder (very common); mydriasis (common); blurred vision (frequency unknown).<ul><li><strong>Very rarely</strong>: acute glaucoma.</li></ul></li><li><strong>Gastrointestinal</strong> — dry mouth, constipation, nausea (very common); diarrhoea, vomiting, tongue oedema (uncommon).<ul><li><strong>Rarely</strong>: salivary gland enlargement, paralytic ileus.</li></ul></li><li><strong>Nervous system</strong> — somnolence, tremors, dizziness, headache, drowsiness, speech disorders (very common). Disturbance in attention, dysgeusia, paraesthesia, ataxia (common).<ul><li><strong>Very rarely:</strong> akathisia, polyneuropathy.</li></ul></li><li><strong>Psychiatric </strong>— aggression (very common); confusional states, agitation, reduced libido (common).<ul><li><strong>Rarely</strong>: delirium (elderly), hallucinations (people with schizophrenia), suicidal thoughts or behaviour.</li></ul></li><li><strong>Renal and urinary</strong> — micturition disorders, erectile dysfunction (common); urinary retention (uncommon).</li><li><strong>Bone fractures</strong> — epidemiological data show that TCAs are associated with an increased risk of fractures. However, the mechanism leading to this increased risk is unclear.</li><li><strong>Other common or very common adverse effects include</strong>:<ul><li>Fatigue</li><li>Hyperhidrosis.</li><li>Hyponatraemia.</li><li>Nasal congestion.</li><li>Orthostatic hypotension.</li><li>Thirst.</li><li>Weight gain.</li></ul></li><li><strong>Other rare or very rare adverse effects include</strong>:<ul><li>Allergic inflammation of the pulmonary alveoli.</li><li>Alopecia, photosensitivity.</li><li>Bone marrow depression.</li><li>Decreased appetite.</li><li>Gynaecomastia</li><li>Hepatic impairment, jaundice.</li><li>Pyrexia.</li><li>Weight loss.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 697e6fb9-c12c-4b6a-b55d-ab1a00fc4ba0 --><!-- end item 7781d9d5-b0e9-4ff5-8ac6-ab1a00fc4b73 -->","subChapters":[]},{"id":"dd1f5ff7-f5ef-529a-b665-181c2739f675","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 01e54521-0e48-4e35-87d5-ab1a00fc57df --><h3>Drug interactions</h3><!-- end field 01e54521-0e48-4e35-87d5-ab1a00fc57df -->","summary":"","htmlStringContent":"<!-- begin item 3b42b68a-c2ad-4438-85be-ab1a00fc57bd --><!-- begin field 8f3b459b-d1d8-433c-9d95-ab1a00fc57df --><ul><li><strong>Adrenergic neurone blockers</strong> (clonidine, guanethidine, reserpine) — the antihypertensive effects may be reduced by TCAs. Monitor blood pressure and adjust dose of antihypertensive if required.</li><li><strong>Lithium </strong>— concurrent us with a TCA may cause neurotoxicity, serotonin syndrome, or neuroleptic malignant syndrome. In addition, both drugs have been associated with QT prolongation or torsades de pointes. Monitor for adverse effects.</li><li><strong>Monoamine oxidase inhibitors</strong> (MAOIs) — concurrent use is contraindicated. Fatal reactions may occur similar to, or the same as, serotonin syndrome.</li><li><strong>Other sedative drugs (alcohol, barbiturates, benzodiazepines)</strong> — TCAs are sedating and co-administration with other sedating drugs may have a synergistic effect.</li><li><strong>Phenothiazines</strong> (for example thioridazine) — concentrations of both drugs may be increased, increasing the risk of tardive dyskinesia and antimuscarinic adverse effects. In addition, dangerous QT prolongation may occur if they are taken concomitantly. Avoid concurrent use, but if this is unavoidable, consider ECG monitoring.</li><li><strong>Phenylephrine</strong> — blood pressure effects of phenylephrine may be increased by TCAs, leading to increased risk of arrhythmias. Dose may need to be reduced in people taking TCAs and then titrated.</li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs)</strong> — TCA concentrations may be increased leading to adverse effects. SSRIs and SNRIs are also associated with QT interval prolongation, possibly increasing the risk of arrhythmias if taken with TCA. Monitor concomitant use.</li><li><strong>Tramadol</strong> — concomitant treatment may increase the risk of serotonin syndrome. Monitor closely.</li><li><strong>Warfarin </strong>— TCAs may affect the prothrombin time in people taking warfarin.</li><li><strong>Drugs which may increase the levels of TCAs include:</strong><ul><li>Antifungals (for example, fluconazole, terbinafine). </li><li>Bupropion.</li><li>Cimetidine. </li><li>Diltiazem, verapamil.</li><li>HIV protease inhibitors (for example, ritonavir).</li></ul></li><li><strong>Drugs which can reduce the levels of TCAs include:</strong><ul><li>Carbamazepine. </li><li>Phenobarbital.</li><li>Rifampicin.</li></ul></li><li><strong>Drugs which prolong the QT interval — </strong>these may increase the likelihood of ventricular arrhythmias when TCA is given concomitantly. Examples include:  <ul><li>Antiarrhythmics — amiodarone, disopyramide, procainamide, and quinidine. Avoid concurrent use.</li><li>Antipsychotics — pimozide, sertindole (avoid concurrent use); olanzapine, clozapine (consider ECG monitoring).</li><li>Other drugs — domperidone, halofantrine, hydroxyzine, mizolastine, sotalol. Avoid concurrent use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019a</a>]</p><!-- end field 8f3b459b-d1d8-433c-9d95-ab1a00fc57df --><!-- end item 3b42b68a-c2ad-4438-85be-ab1a00fc57bd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}